Pathogenetic mechanisms of anemic syndrome formation in patients with inflammatory bowel diseases
https://doi.org/10.33667/2078-5631-2021-20-29-34
Abstract
Inflammatory bowel diseases are an urgent public health problem and are often complicated by the development of anemic syndrome. Significant progress has been made in the treatment of ulcerative colitis and Crohn's disease, but the correction of associated anemia in most cases remains insufficient. This article describes in detail the pathogenetic mechanisms of the formation of anemic syndrome in inflammatory bowel diseases, as well as possible ways to correct this condition.
About the Authors
Yu. P. Uspenskiy
Saint Petersburg State Pediatric Medical University; First Saint Petersburg State Medical University n. a. I. P. Pavlov
Russian Federation
Russian Federation
Uspensky Yuri P., DM Sci, professor, head of Dept of Faculty Therapy; professor at Dept of Internal Medicine of Faculty of Dentistry
Yu. A. Fominykh
Saint Petersburg State Pediatric Medical University; First Saint Petersburg State Medical University n. a. I. P. Pavlov
Russian Federation
Russian Federation
Fominykh Yulia A., DM Sci, professor at Dept of Faculty Therapy; associate professor at Dept of Internal Medicine of Faculty of Dentistry
K. N. Nadzhafova
Saint Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Nadzhafova Kamalya N., assistant of Dept of Faculty Therapy
O. I. Veduta
Saint Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Veduta Olesya I., third-year student of Pediatric Faculty
References
1. Veselov A. V., Belousova E. A., Bakulin I. G., Uspensky Yu.P., Dreval' R.O., Shkurko T.V., Kashnikov V.N., Fominyh Yu.A., Knyazev O.V., Romanov R.I., Skalinskaya M. I., Shipicyn V. V. Assessment of the economic burden and current state of the organization of drug provision for patients with immuno-inflammatory diseases (on the example of ulcerative colitis and crohn's disease) in the Russian Federation. 2020; 28 (S2): 1137–1145. (In Russ.)
2. Uspensky Yu.P., Nadzhafova K. N., Fominykh Yu.A., Dreval R. O., Ivanov S. V., Shotik A.V., Filippova V.N. Extraterestinal lesions in inflammatory bowel diseases: focus on the hepatobiliary system. Farmateka. 2021; 28 (2): 36–42. (In Russ.) DOI: 10.18565/pharmateca.2021.2.36–42
3. N. Murawska, A. Fabisiak, J. Fichna. Anemia of Chronic Disease and Iron Deficiency Anemia in Inflammatory Bowel Diseases: Pathophysiology, Diagnosis, and Treatment. Inflamm Bowel Dis. 2016; 22 (5): 1198–208. DOI: 10.1097/ MIB.0000000000000648
4. Weiss G., Gasche C. Pathogenesis and treatment of anemia in inflammatory bowel disease. Haematologica. 2010; 95: 175–8.
5. Ivanov S.V., Uspensky Yu.P., Fominyh Yu.A., Horoshilov I.E. Anemia in ulcerative colitis: nutritional aspects. Medicina: teoriya i praktika. 2018; 3 (1): 34–35.
6. Beard J. One person’s view of iron deficiency, development, and cognitive function. Am J ClinNutr. 1995; 62 (4): 709–710.
7. Anushenko A. O., Potapov A. S., Cimbalova E. G., Gordeeva O. B. Anemia in inflammatory bowel diseases in children. Voprosy sovremennoj pediatrii. 2016; 15 (2): 128–140. DOI: 10.15690/vsp.v15i2.1530.
8. Gomollon F., Gisbert J. P. Anemia and inflammatory bowel diseases. World J. Gastroenterol.– 2009; 15: 4659–65.
9. Uspensky Yu.P., Ivanov S.V., Majorova O.V., Fominyh Yu.A. Inflammatory bowel diseases and obesity: current state of the problem. Medicinskij alfavit. 2020; 37: 29–34. (In Russ).
10. Arnold J., Sangwaiya A., Manglam V., et al. Presence of hepcidin‑25 in biological fluids: Bile, ascitic and pleural fluids. World J Gastroenterol. 2010; 6 (17): 2129–2133. DOI: 10.3748/wjg.v16.i17.2129.
11. Pakoz Z., Cekic C., Arabul M., et al. Evaluation of the Correlation between Hepcidin Serum Levels and Disease Activity in Inflammatory Bowel Disease. Gastroenterol Res Pract. 2015; 810942. DOI: 10.1155/2015/810942.
12. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 06 (5704): 2090–3.
13. Johnson D., Babele H., Johnston K., Tennant J., Srai S.K., Sharp P. Tumour necrosis factor alpha regulates iron transport and transporter expression in human intestinal epithelial cells. FEBS Lett. 2004; 573 (1–3): 195–01.
14. Knutson M.D., Oukka M., Koss L.M., Aydemir F., Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci USA. 2005; 102 (5): 1324–8. DOI: 10.1073/PNAS.0409409102
15. Мeans R.T. Recent developments in the anemia of chronic disease. Curr Hematol Rep. 2003; 2 (2): 116–21.
16. Weiss G., Goodnough L. Anemia of chronic disease. N Engl J Med. 2005; 352 (10): 1011–1023. DOI: 10.1056/nejmra041809.
17. Sadygova G.G. Anemia in inflammatory bowel diseases. Koloproktologiya. 2016; 3 (57): 84–90. (In Russ).
18. Pavlov A. D. Biological and clinical role of erythropoietin and its receptor in non-hematopoietic tissues. Voprosy gematologii, onkologii I immunopatologii v pediatrii. 2004; 3(1): 12–20. (In Russ).
19. Pavlov A.D., Morshchakova EF. Sindrom neadekvatnoi produktsii eritropoetina na anemiyu. Gematol Transfuziol. 1999; 44 (3): 30–32. (In Russ).
20. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res. 1998; 18 (8): 55–559. DOI: 10.1089/jir.1998.18.555.
21. Wine E., Mack D., Hyams J., et al. Interleukin‑6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis. J Crohns Colitis. 2013; 7 (11): 916–922. DOI: 10.1016/j.crohns.2012.12.012.
22. Basseri R., Nemeth E., Vassilaki M., et al. Hepcidin is a key mediator of anemia of inflammation in Crohn’s disease. J Crohns Colitis. 2013; 7 (8): 286–291. DOI: 10.1016/j.crohns.2012.10.013.
23. Gisbert J.P., Gomollón F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am.J. Gastroenterol. 2008; 103: 1299–1307.
24. Noskova K.K., Lishchinskaya A.A., Parfenov A.I., Knyazev O.V., Varvanina G.G., Drozdov V.N. The risk of developing and clinical and pathogenetic features of anemia against the background of basic therapy of inflammatory bowel diseases. Eksperimental'naya i klinicheskaya gastroenterologiya. 2011; 10: 12–17 (In Russ).
25. Hayat A. Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res. 2008; 6 (3–4): 93–102. DOI: 10.3121/cmr.2008.811.
26. Toblli J., Cao G, Olivieri L., et al. Comparison of the renal, c ardiovascular and hepatic toxicity data of original intravenous ironcompounds. Nephrol Dial Transplant. 2010; 25 (11): 3631–3140. DOI: 10.1093/ndt/gfq260.
27. Avdeev V.G., Moiseev S.V. Anemiya pri bolezni Krona. Klinicheskaya farmakologiya i terapiya. 2013; 22 (1): 1–6. (In Russ).
28. Moore R., Gaskell H., Rose H., Allan J. Meta-analysis of efficacyand safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disorders. 2011; 11: 4. DOI: 10.1186/1471–2326–11–4.
29. Kulnigg S., Stoinov S., Simanenkov V. A novel intravenousiron formulation for treatment of anemia in inflammatory boweldisease: the ferric carboxymaltose (FERINJECT®) randomized controlled trial. Am J Gastroenterol. 2007; 103 (5): 1182–1192. DOI: 10.1111/j.1572–0241.2007.01744.x.
30. Littlewood T., Bajetta E., Nortier J., et al. Effects of epoetinalfaon hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double blind, placebo controlled trial. J Clin Oncol. 2001; 19 (11): 2865–2874.
31. Kaltwasser J., Kessler U., Gottschalk R., et al. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol. 2001; 28 (11): 2430–2436.
32. Rumyantsev A. G., Morshchakova E. F., Pavlov A. D. Eritropoetin: diagnostika, profilaktika I lechenie anemii. Moscow; 2003. 448 p. (In Russ).
33. Yasuda Y., Fujita Y., Matsuo T., et al. Erythropoietin regulatestumour growth of human malignancies. Carcinogenesis. 2003; 24 (9): 1021–1029. DOI: 10.1093/carcin/bgg126.
34. European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. Journal of Crohn’s and Colitis. 2015. 9 (3): 211–222.
Review
For citations:
Uspenskiy Yu.P., Fominykh Yu.A., Nadzhafova K.N., Veduta O.I. Pathogenetic mechanisms of anemic syndrome formation in patients with inflammatory bowel diseases. Medical alphabet. 2021;(20):29-34. (In Russ.) https://doi.org/10.33667/2078-5631-2021-20-29-34
Views:
369
Email this article 